NEW (B22H22)2 FOR NEUTRON CAPTURE AND DIAGNOSTICS

描述(改编自申请)：硼中子俘获疗法 治疗癌症(BNCT)已进入I期和II期临床试验。 多面体硼氢化物在正在进行的试验中占主导地位。 氨基等生物分子的许多多面体硼烷和碳硼基衍生物 酸、核苷酸、核酸、卟啉、抗体等 准备好尽可能多的下一代BNCT试剂。这种衍生品通常是 基于B-10或B-12机笼。一种新的[B22H22]2-的简便合成 发现了由NaBH4(或富含B-10的NaBH4)形成的多面体笼子。 从结构上讲，它可以被认为是十硼烷(B10H14)和 [B12H12]2笼，是许多BNCT试剂的两种主要起始原料。 第一阶段的具体目标是制备卡波兰基的衍生物 [B22H22]2笼用[B22H22]2-的碳硼酰衍生物取代 通常的B10或B12笼子会立即为BNCT制造可能的生物分子 硼的含量增加了两倍。[B22H22]2的另一项申请- 将它附着在DNA或多肽探针上，用于新的专利 诊断技术。 建议的商业应用：不可用

DESCRIPTION (Adapted from the application): Boron Neutron Capture Therapy (BNCT) for treatment of cancer has entered Phase I & II clinical trials. Polyhedral boron hydrides figure predominantly in the ongoing trials. Many polyhedral borane and carboranyl derivatives of biomolecules such as amino acids, nucleotides, nucleic acids, porphyrins, antibodies, etc. have been prepared as possible next generation BNCT agents. Such derivatives are usually based upon B-10 or B-12 cages. A convenient synthesis of a novel [B22H22]2- polyhedral cage from NaBH4 (or B-10 enriched NaBH4) has been discovered. Structurally it may be considered a hybrid of decaborane (B10H14) and the [B12H12]2- cage, the two principal starting materials for many BNCT agents. The specific aim of Phase I is to prepare a carboranyl derivative of the [B22H22]2- cage. Substitution of a carboranyl derivative of [B22H22]2- for the usual B10 or B12 cage would immediately make possible biomolecules for BNCT with a two-fold increase in boron content. Another application for [B22H22]2- would be its attachment to DNA or peptide probes for use in a new patented diagnostic technique. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE